Mylan has announced that it has acquired “exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications” from Pfizer, along with “multi-dose dry powder inhaler technology.” The company says that it plans to submit an NDA for the product as a new chemical entity and will develop combination products using the compound as well.
Mylan CEO Heather Bresch said, “This acquisition further expands Mylan’s growing respiratory franchise, building upon the products we already have in development, such as our generic Advair program and our combination product for the treatment of chronic obstructive pulmonary disease (COPD). By adding a novel LAMA compound to our capabilities, we will have the opportunity to bring additional combination products to market, including triple-combination therapies, and further differentiate Mylan as a leader in this important therapeutic area.”
Only geographic details about marketing rights were included in the announcement. “All other financial terms and product details remain confidential,” the company said.
Read the Mylan press release.
